-2.11%
-37.67%
-37.95%
-68.55%
-79.32%
-82.73%
-89.92%
AI Spotlight on LFWD
Company Description
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa.The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic.It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors.
The company was formerly known as Argo Medical Technologies Ltd.ReWalk Robotics Ltd.was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Market Data
| Last Price | 1.39 |
| Change Percentage | -2.11% |
| Open | 1.41 |
| Previous Close | 1.42 |
| Market Cap ( Millions) | 15 |
| Volume | 167415 |
| Year High | 7.7 |
| Year Low | 1.36 |
| M A 50 | 1.82 |
| M A 200 | 3.28 |
Financial Ratios
| FCF Yield | -151.05% |
| Dividend Yield | 0.00% |
| ROE | -48.96% |
| Debt / Equity | 2.89% |
| Net Debt / EBIDTA | -5.70% |
| Price To Book | 2.46 |
| Price Earnings Ratio | -4.32 |
| Price To FCF | -0.66 |
| Price To sales | 0.59 |
| EV / EBITDA | -0.91 |
News
- Jan -13 - Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
- Jan -13 - Lifeward Cancels Its Extraordinary General Meeting of Shareholders
- Jan -08 - Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Jan -07 - Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Dec -27 - Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
- Nov -19 - Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons
- Nov -12 - Lifeward Ltd. (LFWD) Q3 2024 Earnings Call Transcript
- Nov -12 - Lifeward (LFWD) Reports Q3 Loss, Lags Revenue Estimates
- Nov -12 - Lifeward Ltd. Reports Third Quarter 2024 Financial Results
- Nov -05 - Lifeward to Report Third Quarter Financial Results on November 12, 2024
- Oct -24 - Lifeward Ltd. to Present at ThinkEquity Conference on Oct 30, 2024
- Sep -24 - Lifeward Launches Direct Sales of AlterG Product Line in Germany
- Sep -12 - ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
- Sep -10 - Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research
- Sep -05 - Lifeward's First Annual Step Challenge Donates €5,000 to German Association for People Living with Spinal Cord Injury
- Sep -04 - Lifeward to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug -15 - ReWalk Robotics Ltd. (LFWD) Q2 2024 Earnings Call Transcript
- Aug -15 - ReWalk Robotics (LFWD) Reports Q2 Loss, Lags Revenue Estimates
- Aug -08 - Lifeward to Report Second Quarter Financial Results on August 15, 2024
- Jul -02 - Lifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Exoskeletons
Expected Growth : 13.13 %
What the company do ?
Exoskeletons from ReWalk Robotics Ltd. are wearable, robotic systems that enable individuals with spinal cord injuries to stand and walk again, promoting independence and improving quality of life.
Why we expect these perspectives ?
ReWalk Robotics Ltd.'s exoskeletons growth is driven by increasing demand for mobility solutions, advancements in robotics and AI, expanding healthcare coverage, and growing awareness of spinal cord injuries. Additionally, strategic partnerships, regulatory approvals, and increasing adoption in rehabilitation centers and hospitals contribute to the 13.13% growth.
Rewalk Robotics Ltd. Products
| Product Range | What is it ? |
|---|---|
| ReWalk Personal Exoskeleton | A wearable robotic exoskeleton that provides individuals with spinal cord injuries (SCI) with the ability to stand and walk independently. |
| ReWalk Rehabilitation Exoskeleton | A robotic exoskeleton designed for use in rehabilitation centers to aid in the treatment of patients with SCI, stroke, and other mobility impairments. |
| ReWalk Clinical Trials | A platform for conducting clinical trials and research studies to advance the development of exoskeleton technology and improve patient outcomes. |
ReWalk Robotics Ltd.'s Porter Forces
Threat Of Substitutes
ReWalk Robotics Ltd. faces moderate threat from substitutes, as there are limited alternative products available in the market, but the company's products are highly specialized and patented, making it difficult for substitutes to emerge.
Bargaining Power Of Customers
ReWalk Robotics Ltd. has a low bargaining power of customers, as the company's products are highly specialized and cater to a specific niche market, giving customers limited bargaining power.
Bargaining Power Of Suppliers
ReWalk Robotics Ltd. has a moderate bargaining power of suppliers, as the company relies on a few key suppliers for its components, but the company's patented technology gives it some bargaining power.
Threat Of New Entrants
ReWalk Robotics Ltd. faces a low threat of new entrants, as the company's products are highly specialized and patented, making it difficult for new entrants to enter the market.
Intensity Of Rivalry
ReWalk Robotics Ltd. operates in a highly competitive market, with several established players, leading to a high intensity of rivalry among competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.93% |
| Debt Cost | 3.95% |
| Equity Weight | 96.07% |
| Equity Cost | 14.29% |
| WACC | 13.88% |
| Leverage | 4.09% |
ReWalk Robotics Ltd. : Quality Control
ReWalk Robotics Ltd. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| IBAB.BR | Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and … |
| REG1V.HE | Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
| MEDI.OL | Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Revenio
A-Score
1-Year Total Return ->
🥈
Ion Beam Applications
A-Score
1-Year Total Return ->
🥉
CellaVision
A-Score
1-Year Total Return ->
4
Medistim
A-Score
1-Year Total Return ->
5
Xvivo Perfusion
A-Score
1-Year Total Return ->
6
